1.67
-0.03 (-2.06%)
| Previous Close | 1.70 |
| Open | 1.72 |
| Volume | 382,246 |
| Avg. Volume (3M) | 817,661 |
| Market Cap | 133,901,272 |
| Price / Earnings (TTM) | 20.81 |
| Price / Earnings (Forward) | 9.83 |
| Price / Sales | 2.36 |
| Price / Book | 2.61 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Profit Margin | 6.54% |
| Operating Margin (TTM) | -40.99% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | 169.80% |
| Total Debt/Equity (MRQ) | 11.58% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | 8.67 M |
| Levered Free Cash Flow (TTM) | -3.29 M |
| Return on Assets (TTM) | 3.53% |
| Return on Equity (TTM) | 10.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Protalix BioTherapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 10.39% |
| % Held by Institutions | 10.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Opaleye Management Inc. | 30 Sep 2025 | 2,580,556 |
| Diametric Capital, Lp | 30 Sep 2025 | 179,984 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |